Analysis of Revenues
Revenues as Reported
AbbVie Inc., income statement, revenues
US$ in millions
| 12 months ended: | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical products | 56,334) | 54,318) | 58,054) | 56,197) | 45,804) | ||||||
| Net revenues | 56,334) | 54,318) | 58,054) | 56,197) | 45,804) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Item | Description | The company |
|---|---|---|
| Net revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). | AbbVie Inc. net revenues decreased from 2022 to 2023 but then increased from 2023 to 2024 not reaching 2022 level. |